KRAS and malignant pleural mesothelioma: We first evaluated resting-state NF-κB activity of five mouse cancer cell lines with defined KRAS mutations and MPE capabilities in syngeneic C57BL/6 mice11: Lewis lung carcinoma (LLC; MPE-competent; KrasG12C), MC38 colon adenocarcinoma (MPE-competent; KrasG13R), AE17 malignant pleural mesothelioma (MPE-competent; KrasG12C), B16F10 skin melanoma, and PANO2 pancreatic adenocarcinoma (both MPE-incompetent and KrasWT) cells.